DrugPatentWatch Database Preview
Drugs in Development Information for TAK-659
» See Plans and Pricing
What is the drug development status for TAK-659?
TAK-659 is an investigational drug.
There have been 340 clinical trials for TAK-659.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are three US patents protecting this investigational drug and fifty-four international patents.
Summary for TAK-659
| US Patents | 3 |
| International Patents | 54 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2018-01-01) |
| Vendors | 11 |
Recent Clinical Trials for TAK-659
| Title | Sponsor | Phase |
|---|---|---|
| Japan Expanded Access Program With Lanadelumab for Japanese Patients With Hereditary Angioedema | Takeda | Phase 3 |
| A Study of TAK-536 in Pediatric Participants From 2 to Less Than 6 Years of Age With Hypertension | Takeda | Phase 3 |
| A Study of Icatibant (TAK-667) in Japanese Children and Adolescents With Acute Attacks of Hereditary Angioedema | Takeda | Phase 3 |
Clinical Trial Summary for TAK-659
Top disease conditions for TAK-659
Top clinical trial sponsors for TAK-659
US Patents for TAK-659
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-659 | Start Trial | Fused heteroaromatic pyrrolidinones as SYK inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-659
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-659 | Argentina | AR081797 | 2029-12-23 | Start Trial |
| TAK-659 | Australia | AU2010333804 | 2029-12-23 | Start Trial |
| TAK-659 | Brazil | BR112012015651 | 2029-12-23 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
